Picotamide versus aspirin in diabetic patients with peripheral arterial disease: has David defeated Goliath?

Prevalence of Peripheral Arterial Disease in Diabetic Patients

Objective: Peripheral Arterial Disease (PAD) is a state characterized by atherosclerotic occlusive disease of lower extremities. Diabetes is the main risk factor for PAD. Material and Methods: To assess the prevalence of PAD, a cross sectional study was performed on 352 diabetic patients who referred to Yazd diabetes research center from 2007 to 2010. Vascular assessment was done by measuring ...

prevalence of peripheral arterial disease in diabetic patients

objective: peripheral arterial disease (pad) is a state characterized by atherosclerotic occlusive disease of lower extremities. diabetes is the main risk factor for pad. material and methods: to assess the prevalence of pad, a cross sectional study was performed on 352 diabetic patients who referred to yazd diabetes research center from 2007 to 2010. vascular assessment was done by measuring t...

Picotamide reduced all-cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease.

A David promoter with Goliath strength.

In this issue of Blood, Nair et al report on a computationally derived hepatocyte-specific cis-regulatory module (HS-CRM8) to accomplish high tissue-specific expression in gene therapy for hemophilia. When HS-CRM8 is introduced upstream of a minimal liver-specific promoter in an adenoassociated virus (AAV) that expresses a codon-optimized hyperactive human factor IX (FIX) mutant (FIX Padua), it...

Peripheral arterial disease in patients with diabetes.

Peripheral arterial disease (PAD) is a chronic, lifestyle-limiting disease and is an independent predictor of cardiovascular and cerebrovascular ischemic events. Despite the recognition that PAD is associated with a marked increase in the risk of ischemic events, this particular manifestation of systemic atherosclerosis is largely underdiagnosed and undertreated. The risk of PAD is markedly inc...